These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 9517377)

  • 21. Potential beneficial metabolic interactions between tamoxifen and isoflavones via cytochrome P450-mediated pathways in female rat liver microsomes.
    Chen J; Halls SC; Alfaro JF; Zhou Z; Hu M
    Pharm Res; 2004 Nov; 21(11):2095-104. PubMed ID: 15587933
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Binding and bioeffects of Ipriflavone on a human preosteoclastic cell line.
    Benvenuti S; Petilli M; Frediani U; Tanini A; Fiorelli G; Bianchi S; Bernabei PA; Albanese C; Brandi ML
    Biochem Biophys Res Commun; 1994 Jun; 201(3):1084-9. PubMed ID: 7517664
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of RPR 102341 on theophylline metabolism and phenacetin O-deethylase activity in human liver microsomes.
    White RB; Heyn H; Stevens JC
    Pharm Res; 1997 Apr; 14(4):512-5. PubMed ID: 9144741
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Which concentration of the inhibitor should be used to predict in vivo drug interactions from in vitro data?
    Ito K; Chiba K; Horikawa M; Ishigami M; Mizuno N; Aoki J; Gotoh Y; Iwatsubo T; Kanamitsu S; Kato M; Kawahara I; Niinuma K; Nishino A; Sato N; Tsukamoto Y; Ueda K; Itoh T; Sugiyama Y
    AAPS PharmSci; 2002; 4(4):E25. PubMed ID: 12645997
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stability, blood partition and plasma protein binding of ipriflavone, an isoflavone derivative.
    Kim SH; Lee JS; Lee MG
    Biopharm Drug Dispos; 1999 Oct; 20(7):355-60. PubMed ID: 10760844
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of ipriflavone on bone changes induced by calcium restricted, vitamin D deficient diet in rats.
    Takenaka M; Nakata M; Tomita M; Nakagawa T; Tsuboi S; Fukase M; Fujita T
    Endocrinol Jpn; 1986 Feb; 33(1):23-7. PubMed ID: 3720677
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics and tissue distribution of ipriflavone, an isoflavone derivative, after intravenous administration to rabbits.
    Kim S; Lee J; Lee M
    Biopharm Drug Dispos; 2000 May; 21(4):147-56. PubMed ID: 11180193
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ipriflavone inhibits phosphoinositide hydrolysis and Ca2+ uptake in the osteoblast-like UMR-106 cells.
    Sortino MA; Aleppo G; Scapagnini U; Canonico PL
    Eur J Pharmacol; 1992 Jul; 226(3):273-7. PubMed ID: 1330635
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Suppressive effect of ipriflavone on bone depletion in the experimental diabetic rat: dose response of ipriflavone.
    Shino A; Tsukuda R; Odaka H; Kitazaki T; Tsuda M; Matsuo T
    Life Sci; 1988; 42(11):1123-30. PubMed ID: 3347142
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Calcitonin secreting property of ipriflavone in the presence of estrogen.
    Yamazaki I; Kinoshita M
    Life Sci; 1986 Apr; 38(17):1535-41. PubMed ID: 3702590
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ipriflavone does not alter bone apatite crystal structure in adult male rats.
    Ghezzo C; Civitelli R; Cadel S; Borelli G; Maiorino M; Bufalino L; Bongrani S
    Calcif Tissue Int; 1996 Dec; 59(6):496-9. PubMed ID: 8939778
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacological implications of ipriflavone against environmental metal-induced neurodegeneration and dementia in rats.
    Hussien HM; Ghareeb DA; Ahmed HEA; Hafez HS; Saleh SR
    Environ Sci Pollut Res Int; 2021 Dec; 28(46):65349-65362. PubMed ID: 34235690
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of flavone treatment on human otosclerotic ossicle organ cultures.
    Sziklai I; Ribári O
    Arch Otorhinolaryngol; 1985; 242(1):67-70. PubMed ID: 4038152
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative bioavailability of two oral formulations of ipriflavone in healthy volunteers at steady-state. Evaluation of two different dosage schemes.
    Acerbi D; Poli G; Ventura P
    Eur J Drug Metab Pharmacokinet; 1998; 23(2):172-7. PubMed ID: 9725477
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ipriflavone, an antiostheophorotic agent.
    Böcskei Z; Simon K; Varga M; Hermecz I
    Acta Crystallogr C; 1996 Apr; 52 ( Pt 4)():1022-4. PubMed ID: 8624237
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Interaction between ipriflavone and other drugs in metabolism in vitro].
    Hu XY; Yao TW
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2004 Jan; 33(1):21-3. PubMed ID: 14966934
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The ipriflavone story].
    György L; Mihály N; Marian EP; István H
    Acta Pharm Hung; 1995 Nov; 65(6):191-4. PubMed ID: 8742624
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A
    Liu RZ; Chen S; Zhang L
    Beilstein J Org Chem; 2022; 18():1107-1115. PubMed ID: 36105730
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Retraction: Ipriflavone and Ipriflavone loaded albumin nanoparticles reverse lipopolysaccharide induced neuroinflammation in rats.
    PLOS ONE Editors
    PLoS One; 2023; 18(11):e0294102. PubMed ID: 37917647
    [No Abstract]   [Full Text] [Related]  

  • 40. Ipriflavone: Background.
    Gennari C
    Calcif Tissue Int; 1997; 61(7):3-4. PubMed ID: 9245388
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.